Agenda Attendees Comments Speakers Participating Organizations

This program was made possible at no cost to the public by the support of our corporate sponsors:

Agenda

Attendees Comments

	"Very informative and well organized. As a layperson, I found I could understand most of the information presented. The speakers addressed the audience without going over their heads. Well Done! Question and answer period was informative and well addressed." "A great opportunity to hear experts in their field present their research work first hand. Sessions accomplished its objectives - Thanks to SynCure and it sponsors and the speakers. Excellent update on screening for cancer." "Well Done! Comprehensive agenda of topics. Fabulous speakers (without exception). Good information expressed in easily understood language (not too technical). Very topical and timely issues addressed. Good AV. I would attend others like it." "Terrific program - organized and presented well. A very nice balance between scientific and lay terminology. Each presenter covered his/her area cogently and effectively." "Presentations were excellent. I especially appreciated how the highly articulate speakers explained complex processes for the average guy on the street." "The speakers were very impressive! Thanks to them, I am leaving today with a little more knowledge of cancer. Questions at the end was an excellent format." "Very well organized, logical presentation, excellent program. Very enjoyable, fast moving, extremely informative." "Very good program, well presented by knowledgeable participants." "Appreciate the opportunity to better understand the disease. Speakers were excellent. Thank you." "The speakers were excellent! Likewise, the topics. The speaker panelists were very informative in their replies to attendees' questions. The program certainly made clear to the attendees that there is an on-going need for a multitude of cancer studies and particularly the need for clinical studies. Having a separate panel to answer all the Q's & A's was very effective. Great idea in meeting format."
		In spite of a severe snow storm and an "orange" terror alert, the program was well attended by cancer patients, family members, medical and patient-support groups...
		Dr. Roger Strair discussing an issue of concern with a family...
		Dr. Howard Kaufman answers questions with family members...
		Dr. Emina Huang discussing advances in colon cancer diagnostics...

Speakers

		Jennifer Eng-Wong, MD, MPH Staff Clinician, Medical Oncology Research Unit National Cancer Institute Bethesda, MD
Jennifer Eng-Wong graduated from SUNY-Stony Brook Medical School. She then went on to complete her Internal Medicine Residency at the University of California, Davis. She did her Medical Oncology Fellowship training at the National Cancer Institute (NCI) in Bethesda, MD and while there became interested in cancer prevention. Dr. Eng-Wong joined the Cancer Prevention Fellowship at the NCI and obtained her MPH at George Washington University s School of Public Health. Her current research interests are breast cancer prevention, and recently she became Staff Clinician in the Medical Oncology Clinical Research Unit at the NCI.
		Gabe Feldman, MD, MPH, MBA, MHA, FACPM Cancer Prevention Chief NYC Department of Health & Mental Hygiene New York, NY
Dr. Feldman is the director of cancer prevention and control for New York City. He is board certified in preventive medicine and public health, and is the former National Director of the American Cancer Society. He co-authored a recent national strategic plan on promoting colon cancer screening in the U.S. and a review of cancer patterns in Ashkenazi Jews. Dr. Feldman was born in Brooklyn, NY and attended the Sackler School of Medicine in Tel Aviv, Israel.
		Emina Huang, MD Assistant Professor of Surgery Columbia University College of Physicians and Surgeons New York, NY
Dr. Huang is a surgeon and researcher specializing in colorectal oncology and endoscopic surgery. She received her MD degree from Stanford University and has previously served on the staff of the Department of Surgery at Ohio State University. Dr. Huang is a member of the American College of Surgeons, North American Taiwanese Medical Association, Association of Women Surgeons and the Society of American Gastrointestinal Endoscopic Surgeons. Dr. Huang s research in the field of endoscopic surgery has been published in several journals.
		Howard L. Kaufman, MD Vice Chairman of Surgical Oncology Columbia University College of Physicians and Surgeons New York, NY
Dr. Kaufman is an academic surgical oncologist and has an active interest in tumor immunology. He has an NIH-funded laboratory pursuing tumor vaccine development and murine models of human cancer. He is board certified in surgery and is the Director of the Interleukin-2 unit located at the Milstein Hospital of Columbia Presbyterian Medical Center. He also heads the Melanoma and Soft Tissue Tumor section within the Department of Surgery. Dr. Kaufman is also Associate Director of the Herbert Irving Comprehensive Cancer Center and holds numerous academic and hospital appointments, including Vice Chairman for Surgical Oncology, Associate Professor of Pathology and Surgery at the College of Physicians and Surgeons of Columbia University and was named the first Doris Duke Clinical Scientist awardee for cancer in 1998. As principal investigator, he has conducted over thirty clinical trials of vaccines and biologic agents in cancer. Currently, he is the principal investigator of a multi-centered vaccine study for the treatment of metastatic colorectal cancer. He is an Associate Editor for Cancer Investigation, serves as a reviewer for many clinical and scientific journals and has numerous publications in the field of tumor immunology and immunotherapy.
		Carol S. Portlock, MD Attending Physician, Lymphoma Memorial Sloan-Kettering Cancer Center Professor of Clinical Medicine, NY Weill Cornell University Medical College New York, NY
Dr. Portlock is best known for her work in Hodgkin s and non-Hodgkin s lymphomas, including her finding that slow-growing lymphomas can simply be monitored for some time before treatment is needed. Her research focuses on new therapies for non-Hodgkin s lymphoma, including initial stem-cell transplantation and immunotherapy. Dr. Portlock received both her AB and MD degrees from Stanford University. Prior to her current appointments, she has been on the staff at both the Stanford and the Yale School of Medicine. She has received grants from many sources to support her research and serves on numerous cancer advisory boards and committees. Dr. Portlock has published extensively on the results of her research, including 24 journal articles and book chapters in just the past three years.
		Roger K. Strair, MD, PhD Associate Professor of Medicine, University of Medicine and Dentistry of NJ Robert Wood Johnson Medical School New Brunswick, NJ
Dr. Strair is a medical oncologist with specific interests in leukemia and lymphoma. In addition to his faculty appointment at the University of Medicine and Dentistry of New Jersey, Dr. Strair is the Director of the Hematologic Malignancies program and the Bone Marrow Transplantation program at the Cancer Institute of New Jersey. He received both his MD degree and his PhD degree (Cell Biology) from the Albert Einstein College of Medicine, Bronx, NY. Dr. Strair has previously been an Assistant Professor of Medicine with the Harvard Medical School and the Yale University School of Medicine. He has published numerous research articles and currently has several grants that support his clinical research on blood cancers.
Dr. Eder was unable to attend due to weather conditions in Boston.		J. Paul Eder, MD Assistant Professor, Harvard Medical School Associate Physician, Dana-Farber Cancer Institute Boston, MA
Dr. Eder is an academic research oncologist with expertise in clinical trials of new cancer drugs and the biochemical mechanisms of drug resistance. In addition to his appointments at Harvard and Dana-Farber, where he is the Clinical Director of the Experimental Therapeutics Program, he is on the clinical staff at Beth Israel Deaconess Hospital and Brigham and Women s Hospital. Dr. Eder received his MD degree from the Georgetown University School of Medicine. Presently, he is an investigator on two clinical studies sponsored by the National Cancer Institute; one involves the angiogenesis inhibitor angiostatin and the other study targets the development of vaccines for multiple myeloma.

Participating Organizations